BioGaia AB (publ) (BIOG_B) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to Biogea Q3 report for 2025. For the first part of the conference call, the participants will be in listen-only mode. During the questions and answers session, participants are able to ask questions by dialing pound key 5 on their telephone keypad. Now I will hand the conference over to CEO Teresa Agnew and CFO Alexander Katsinas. Please go ahead. Hi, this is Teresa Agnew, CEO of BioGaia. We are here to present our Q4 results. So first off, our financial highlights. We had strong organic growth for the quarter of 32%. We had an EBIT margin of 27% and overall free cash flow at 77 million SACs. In terms of an overall summary, for the year, we hit 1.5 billion SEC, an increase of 14% in organic growth compared to last year, and overall 8% growth adjusted for currency effects. In the fourth quarter, as I said, we had 32% organic growth and 21% including currency effects. We did experience some order variability in the fourth quarter, as is typical across some of our quarters, and that was approximately 35 million SEC. Our overall operating profit for the quarter was 121 million SEC, which is an increase of 17%, and our EBIT margin, as I said, was 27% for the quarter. In terms of our strategy, we have three strategic pillars. Our first is what we call grow the core. And these are our core health areas of which gut health, colic is a part of that, for instance. oral health and immune health are our three core health areas that we focus on through our marketing and commercial excellence. Our second strategic area is what we call expansion through direct markets. So I'll talk about this a little bit in terms of how we have been expanding our business. through new direct markets in 2025. And then our third strategic pillar is what we call breakthrough innovation. So t...